Aquestive Therapeutics Inc Net Assets
Aquestive Therapeutics Inc net assets. Based on the latest financial reports, Aquestive Therapeutics Inc (AQST) has net assets worth $-34.05 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($141.12 Million) and total liabilities ($175.18 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore AQST shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-34.05 Million |
| % of Total Assets | -24.13% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 286.02 |
Net Assets of Aquestive Therapeutics Inc (2005–2025)
Net assets of Aquestive Therapeutics Inc from 2005 to 2025. This chart illustrates how Aquestive Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See AQST equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Aquestive Therapeutics Inc (2005–2025)
The table below shows the annual net assets of Aquestive Therapeutics Inc from 2005 to 2025. For live market cap and overall valuation, see Aquestive Therapeutics Inc (AQST) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-33.66 Million | +44.04% |
| 2024-12-31 | $-60.16 Million | +43.51% |
| 2023-12-31 | $-106.49 Million | +10.18% |
| 2022-12-31 | $-118.55 Million | -44.34% |
| 2021-12-31 | $-82.13 Million | -69.36% |
| 2020-12-31 | $-48.50 Million | -692.18% |
| 2019-12-31 | $-6.12 Million | -160.73% |
| 2018-12-31 | $10.08 Million | +138.04% |
| 2017-12-31 | $-26.50 Million | -50.75% |
| 2016-12-31 | $-17.58 Million | -169.57% |
| 2006-12-31 | $25.26 Million | +441.54% |
| 2005-12-31 | $4.67 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aquestive Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 43515500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Aquestive Therapeutics Inc Net Assets Breakdown (December 2025)
Aquestive Therapeutics Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $122.00K | % |
| Other Components | $413.21 Million | % |
| Total Equity | $-33.66 Million | 100.00% |
Aquestive Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Aquestive Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Soling Industrial Co Ltd
SHE:002766
|
$488.19 Million |
|
Changchun Gas Co Ltd
SHG:600333
|
$488.38 Million |
|
Zhangjiagang Guangda Special Material Co Ltd
SHG:688186
|
$488.43 Million |
|
Lake Materials Co. Ltd.
KQ:281740
|
$488.65 Million |
|
Grupo Supervielle S.A
F:189A
|
$487.93 Million |
|
China Oil HBP Science & Technology Co Ltd
SHE:002554
|
$487.91 Million |
|
Beijing Jingcheng Machinery Electric Co Ltd
SHG:600860
|
$487.84 Million |
|
Northern United Publishing & Media Group Co Ltd
SHG:601999
|
$487.73 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aquestive Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -60,156,000 to -33,662,000, a change of 26,494,000.
- Net loss of 83,784,000 reduced equity.
- New share issuances of 100,654,000 increased equity.
- Other factors increased equity by 9,624,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-83.78 Million | -248.9% |
| Share Issuances | $100.65 Million | +299.01% |
| Other Changes | $9.62 Million | +28.59% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Aquestive Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-0.72 | $3.89 | x |
| 2017-12-31 | $-1.32 | $3.89 | x |
| 2018-12-31 | $0.49 | $3.89 | x |
| 2019-12-31 | $-0.24 | $3.89 | x |
| 2020-12-31 | $-1.44 | $3.89 | x |
| 2021-12-31 | $-2.16 | $3.89 | x |
| 2022-12-31 | $-2.43 | $3.89 | x |
| 2023-12-31 | $-1.74 | $3.89 | x |
| 2024-12-31 | $-0.69 | $3.89 | x |
| 2025-12-31 | $-0.28 | $3.89 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aquestive Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -188.09%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-69.74%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -177.56% | -390.16% | 0.17x | 2.64x | $-8.75 Million |
| 2006 | -50.48% | -469.69% | 0.10x | 1.08x | $-15.28 Million |
| 2016 | 0.00% | -18.54% | 1.31x | 0.00x | $-7.84 Million |
| 2017 | 0.00% | -13.36% | 1.55x | 0.00x | $-6.29 Million |
| 2018 | -608.89% | -91.02% | 0.78x | 8.62x | $-62.38 Million |
| 2019 | 0.00% | -125.92% | 0.67x | 0.00x | $-65.63 Million |
| 2020 | 0.00% | -121.67% | 0.73x | 0.00x | $-50.93 Million |
| 2021 | 0.00% | -138.77% | 0.82x | 0.00x | $-62.33 Million |
| 2022 | 0.00% | -114.11% | 0.84x | 0.00x | $-42.55 Million |
| 2023 | 0.00% | -15.56% | 0.88x | 0.00x | $2.78 Million |
| 2024 | 0.00% | -76.68% | 0.57x | 0.00x | $-38.12 Million |
| 2025 | 0.00% | -188.09% | 0.28x | 0.00x | $-80.42 Million |
Industry Comparison
This section compares Aquestive Therapeutics Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $100,165,415
- Average return on equity (ROE) among peers: -25.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aquestive Therapeutics Inc (AQST) | $-34.05 Million | -177.56% | N/A | $488.07 Million |
| Aurora Cannabis Inc (ACB) | $1.71 Million | -2.57% | 0.01x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $166.09 Million | -138.50% | 2.72x | $143.73 Million |
| Akanda Corp (AKAN) | $-11.99 Million | 0.00% | 0.00x | $562.47K |
| Akebia Ther (AKBA) | $131.00 Million | -46.35% | 0.09x | $189.26 Million |
| Alkermes Plc (ALKS) | $161.37 Million | -10.45% | 1.50x | $7.61 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-25.36 Million | 0.00% | 0.00x | $3.22 Billion |
| Amphastar P (AMPH) | $329.25 Million | 3.20% | 0.30x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $208.93 Million | -62.22% | 17.18x | $5.92 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-44.54 Million | 0.00% | 0.00x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $85.19 Million | 5.07% | 0.51x | $279.44 Million |
About Aquestive Therapeutics Inc
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulati… Read more